The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis

Fundamental and Clinical Pharmacology

Volumn 25, Issue 6, 2011, Pages 723-733

  Esmaily, Hadi ^a   Vaziri Bami, Amanollah ^b   Miroliaee, Amir Ebrahim ^b   Baeeri, Maryam ^b   Abdollahi, Mohammad ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colitis; Inflammatory bowel disease; NF B; Oxidative stress; Silibinin; Ursodeoxycholic acid

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MYELOPEROXIDASE; SILIBININ; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RAT;

ANIMALS; ANTIOXIDANTS; CHOLAGOGUES AND CHOLERETICS; COLITIS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; MALE; NF-KAPPA B; RATS; RATS, WISTAR; SILYMARIN; TRINITROBENZENESULFONIC ACID; URSODEOXYCHOLIC ACID;

EID: 80054928143     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00893.x     Document Type: Article

References (46)

1. Sanchez-Munoz F., Dominguez-Lopez A., Yamamoto-Furusho J.K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. (2008) 14 4280-4288.
2. Hanauer S.B. Inflammatory bowel disease: epidemiology, and therapeutic opportunities. Inflamm. Bowel Dis. (2006) 1 S3-S9.
3. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology (2004) 126 1620-1633.
4. Rahimi R., Nikfar S., Rahimi F. et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig. Dis. Sci. (2008) 53 2524-2531.
5. Bouma G., Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. (2003) 3 521-533.
6. Neurath M.F., Becker C., Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut (1998) 43 856-860.
7. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. (2003) 10 45-65.
8. Scheinman R.I., Cogswell P.C., Lofquist A.K. et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science (1995) 270 283-286.
9. Rahimi R., Mozaffari S., Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig. Dis. Sci. (2009) 54 471-480.
10. Gazák R., Walterová D., Kren V. Silybin and silymarin - new and emerging applications in medicine. Curr. Med. Chem. (2007) 14 315-338.
11. Rainone F. Milk thistle. Am. Fam. Physician (2005) 72 1285-1288.
12. Kang J.S., Jeon Y.J., Park S.K. et al. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochem. Pharmacol. (2004) 67 175-181.
13. Malihi F., Hosseini-Tabatabaei A., Esmaily H. et al. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus. Cent. Eur. J. Biol. (2009) 4 369-380.
14. Manna S.K., Mukhopadhyay A., Van N.T. et al. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J. Immunol. (1999) 163 6800-6809.
15. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs (2001) 61 2035-2063.
16. Esmaily H., Hosseini-Tabatabaei A., Rahimian R. et al. On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Cent. Eur. J. Biol. (2009) 4 204-213.
17. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J. Hepatol. (2001) 35 134-146.
18. Joo S.S., Kang H.C., Won T.J. et al. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and nitric oxide in rat microglia. Arch. Pharm. Res. (2003) 26 1067-1073.
19. Mitsuyoshi H., Nakashima T., Sumida Y. et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem. Biophys. Res. Commun. (1999) 263 537-542.
20. Güldütuna S., Zimmer G., Imhof M. et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology (1993) 104 1736-1744.
21. Rodrigues C.M., Fan G., Ma X. et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. (1998) 101 2790-2799.
22. Joo S.S., Won T.J., Lee D.I. Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch. Pharm. Res. (2004) 27 954-960.
23. Lukivskaya O., Patsenker E., Buko V.U. Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci. (2007) 80 2397-2402.
24. Byrne A.M., Foran E., Sharma R. et al. Bile acids modulate the Golgi membrane fission process via a protein kinase Ceta and protein kinase D-dependent pathway in colonic epithelial cells. Carcinogenesis (2010) 31 737-744.
25. Kullmann F., Arndt H., Gross V. et al. Beneficial effect of ursodeoxycholic acid on mucosal damage in trinitrobenzene sulphonic acid-induced colitis. Eur. J. Gastroenterol. Hepatol. (1997) 9 1205-1211.
26. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. (2002) 20 495-549.
27. Jurjus A.R., Khoury N.N., Reimund J.M. Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods (2004) 50 81-92.
28. Astaneie F., Afshari M., Mojtahedi A. et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch. Med. Res. (2005) 36 376-381.
29. Nakhai L.A., Mohammadirad A., Yasa N. et al. Benefits of Zataria multiflora Boiss in Experimental Model of Mouse Inflammatory Bowel Disease. Evid Based Complement Alternat. Med. (2007) 4 43-50.
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. (1976) 72 248-254.
31. Blumberg R.S., Saubermann L.J., Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. (1999) 11 648-656.
32. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene (2006) 25 6680-6684.
33. Sandborn W.J., Hanauer S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. (1999) 5 119-133.
34. Kreydiyyeh S.I., Al-Sadi R. The mechanism by which interleukin-1 beta reduces net fluid absorption from the rat colon. Eur. Cytokine Netw. (2002) 13 358-363.
35. Ishizaki K., Iwaki T., Kinoshita S. et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur. J. Pharmacol. (2008) 578 57-64.
36. Rezaie A., Parker R.D., Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci. (2007) 52 2015-2021.
37. Rezaie A., Ghorbani F., Eshghtork A. et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-β1 in relation to disease activity in Crohn's disease patients. Ann. N Y Acad. Sci. (2006) 1091 110-122.
38. Dalle-Donne I., Rossi R., Giustarini D. et al. Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta (2003) 329 23-38.
39. Del Rio D., Stewart A.J., Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. (2005) 15 316-328.
40. Pradhan S.C., Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res. (2006) 124 491-504.
41. Salari P., Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: role of ATP. Recent Pat Endocr. Metab. Immune Drug Discov. (2009) 3 69-75.
42. Rahimi R., Nikfar S., Rezaie A., Abdollahi M. A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn's disease. Clin. Ther. (2006) 28 1983-1988.
43. Nikfar S., Rahimi R., Rahimi F., Derakhshani S., Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis. Colon Rectum (2008) 51 1775-1780.
44. Rahimi R., Nikfar S., Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed. Pharmacother. (2007) 61 75-80.
45. Hosseini-Tabatabaei A., Abdollahi M. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm. Allergy Drug Targets (2008) 7 129-135.
46. Gluud C., Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. (2002) CD000551.